Hubei Gedian Humanwell Pharmaceutical Abiraterone Acetate Hubei Gedian Humanwell Pharmaceutical Abiraterone Acetate

X

Find Drugs in Development News & Deals for Abiraterone Acetate

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

EU WC

EU WC

Listed Suppliers

Listed Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

JP

0

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • TABLET;ORAL - 250MG
  • TABLET;ORAL - 500MG

Details:

Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga® (abiraterone acetate), is an anticancer medication. It works by preventing androgen (male hormone) production in man.


Lead Product(s): Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Abiraterone Acetate-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 19, 2020

Details:

Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.


Lead Product(s): Abiraterone Acetate,Prednisolone

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 17, 2022

Tiefenbacher Compnay Banner

78th STLE Annual Meeting

Not Confirmed

envelop Contact Supplier

Details:

Under the agreement, Novartis obtains worldwide development and commercialization rights of ARV-766, Arvinas’ second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer and also its preclinical AR-V7 program.


Lead Product(s): Luxdegalutamide,Abiraterone Acetate

Therapeutic Area: Oncology Product Name: ARV-766

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

Deal Size: $1,160.0 million Upfront Cash: $150.0 million

Deal Type: Licensing Agreement April 11, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

JNJ-64091742 (niraparib) is an orally administered, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor that is currently being studied for the treatment of metastatic castrationresistant prostate cancer with BRCA alterations.


Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: JNJ-64091742

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 22, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lynparza (olaparib) is a first-in-class PARP inhibitor and approved in combination with abiraterone for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.


Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 24, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

USFDA approves FoundationOne®CDx to be used as a companion diagnostic for AKEEGA (niraparib and abiraterone acetate), the first-and-only dual action tablet, which was approved for deleterious BRCA-mutated metastatic castration-resistant prostate cancer in adults.


Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Akeega

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

KEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, for the treatment of adult patients with BRCA-positive mCRPC.


Lead Product(s): Niraparib Tosylate,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Akeega

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 11, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment which leads to the trapping of PARP bound to DNA single-strand breaks, stalling of replication forks, their collapse and the generation of DNA double-strand breaks and cancer cell death.


Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Merck & Co

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 13, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Lynparza (olaparib), a first-in-class PARP inhibitor, gets FDA approval for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer. It is already approved in the US for HRR gene-mutated mCRPC.


Lead Product(s): Olaparib,Abiraterone Acetate,Prednisone

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content